Newsroom

Press Releases
Presentations

Investors

Overview
Warrant Exercise Inquiries
Restricted Stock Inquiries
Notice to Stockholders
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance

Clinical Trial Enrollment

COVID-19 Long-Haulers
COVID-19 Mild to Moderate
COVID-19 Severe or Critical
Nonalcoholic Steatohepatitis (NASH)
Triple-Negative Breast Cancer

Contact

Home
About CytoDyn
- Meet CytoDyn
Our Science
Pipeline
- Overview
- HIV
- Cancer
- GVHD
- COVID-19
Our Team
- Management Team
- Board of Directors
Careers
- Now Hiring
Scientific Board of Advisors
Newsroom
Investors
Clinical Trial Enrollment
Contact

FOR THE LATEST DEVELOPING NEWS Click Here

Enrollment Locations for Open Label Extension (OLE)

Dr. Yang – Leronlimab in IDSA Publication

Investment Community Webcast - Thursday, July 22

Potential Future of Leronlimab in HIV PrEP

Supply and Distribution Deal with Macleods Pharma

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab and Glioblastoma - Published April 2021

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Leronlimab Published in Journal of Translational Autoimmunity

Nature Communications: Leronlimab and HIV

Case Study - Journal of Translational Autoimmunity

Dr. Seethamraju - Special isirv-AVG Virtual Conference

TNBC Presentation – Dr. Kelly

Leronlimab Potential in HIV PrEP

CD15 Patients’ Testimonies

Long-Hauler Trial Endpoints

CytoDyn Granted US Patent for Methods of Treating Coronavirus Infection with Leronlimab

IR Calendar

Investors

Overview
Warrant Exercise Inquiries
Restricted Stock Inquiries
Notice to Stockholders
News / Events
Company Info
Financial Info
Stock Data
SEC Filings
Governance

News / Events
Overview
Press Releases
In The News
IR Calendar
Email Alerts

Investment Community Conference Call

Mar 5, 2020 • 4:00 pm EDT

Webcast

Email Alerts
Tear Sheet
Contacts
RSS News Feed

© 2021 CytoDyn Inc. All Rights Reserved.

Privacy Policy Disclaimer Sitemap